Temozolomide chemotherapy in recurrent oligodendroglioma

被引：62
|
作者：
van den Bent, MJ
Keime-Guibert, F
Brandes, AA
Taphoorn, MJB
Kros, JM
Eskens, FALM
Carpentier, AF
机构：
[1] Univ Rotterdam Hosp, Rotterdam Canc Ctr, Dept Neurooncol, NL-3008 AE Rotterdam, Netherlands
[2] Univ Rotterdam Hosp, Rotterdam Canc Ctr, Dept Pathol, NL-3008 AE Rotterdam, Netherlands
[3] Univ Rotterdam Hosp, Rotterdam Canc Ctr, Dept Oncol, NL-3008 AE Rotterdam, Netherlands
[4] Hop La Pitie Salpetriere, Federat Neurol Marazin, Paris, France
[5] Univ Padua, Azienda Osped, Div Med Oncol, I-35100 Padua, Italy
[6] Univ Med Ctr Utrecht, Dept Neurol, Utrecht, Netherlands
来源：
NEUROLOGY | 2001年 / 57卷 / 02期
关键词：
D O I：
10.1212/WNL.57.2.340
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The authors determined the tolerance, response rate, and duration of recurrent anaplastic oligodendroglioma in 30 patients to temozolomide given orally at 150 to 200 mg/m(2) on days 1 through 5 in cycles of 28 days. Nine patients responded: 7 of 27 patients (26%) treated with temozolomide after prior PCV chemotherapy and 2 of 3 chemotherapy-naive patients (both complete response). Median time to progression in responding patients was 13 months. Temozolomide shows promise and has an acceptable safety profile in recurrent anaplastic oligodendroglial tumors. Patients not responding to PCV may respond to temozolomide.
引用
收藏
页码：340 / 342
页数：3
相关论文
共 50 条
  • [31] Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma
    Chamberlain, M
    Tsao-Wei, D
    Groshen, S
    NEURO-ONCOLOGY, 2005, 7 (03) : 388 - 388
  • [32] Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma
    Chamberlain, MC
    Tsao-Wei, DD
    Groshen, SG
    NEUROLOGY, 2005, 64 (06) : A47 - A47
  • [33] Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme
    Chamberlain, MC
    Tsao-Wei, DD
    CANCER, 2004, 100 (06) : 1213 - 1220
  • [34] Salvage chemotherapy with CPT-11 for recurrent temolozomide-refractory anaplastic oligodendroglioma
    Chamberlain, M. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy
    van den Bent, MJ
    Kros, JM
    Heimans, JJ
    Pronk, LC
    van Groeningen, CJ
    Krouwer, HGJ
    Taphoorn, MJB
    Zonnenberg, BA
    Tijssen, CC
    Twijnstra, A
    Punt, CJA
    Boogerd, W
    NEUROLOGY, 1998, 51 (04) : 1140 - 1145
  • [36] Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma
    Thomas Zander
    Willy Nettekoven
    Jürgen A. Kraus
    Hendrik Pels
    Yon D. Ko
    Hans Vetter
    Thomas Klockgether
    Uwe Schlegel
    Journal of Neurology, 2002, 249 : 1055 - 1057
  • [37] Pneumocystis Pneumonia In A Patient Treated With Temozolomide For Malignant Oligodendroglioma
    Yadav, R.
    Pascal, W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [38] Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma
    Zander, T
    Nettekoven, W
    Kraus, JA
    Pels, H
    Ko, YD
    Vetter, H
    Klockgether, T
    Schlegel, U
    JOURNAL OF NEUROLOGY, 2002, 249 (08) : 1055 - 1057
  • [39] Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma and anaplastic oligoastrocytoma with or without radiation therapy
    Mikkelsen, Tom
    Doyle, Tom
    Paleologos, Nina
    Schultz, Lonni
    Croteau, David
    NEURO-ONCOLOGY, 2006, 8 (04) : 447 - 447
  • [40] Seizure response to temozolomide chemotherapy in patients with WHO grade II oligodendroglioma: a single-institution descriptive study
    Haggiagi, Aya
    Avila, Edward K.
    NEURO-ONCOLOGY PRACTICE, 2019, 6 (03) : 203 - 208
12345